Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA TO REPORT TO COSMETICS FIRMS ON PRODUCTS WITH ABOVE-NORMAL ADVERSE REACTION

This article was originally published in The Rose Sheet

Executive Summary

FDA TO REPORT TO COSMETICS FIRMS ON PRODUCTS WITH ABOVE-NORMAL ADVERSE REACTION rates based on data obtained from a planned FDA cosmetics adverse reaction hotline. A Nov. 10 Federal Register notice announced that FDA is seeking clearance from the Office of Management and Budget to set up a hotline program designed "to enable the public to report directly to FDA any adverse reactions they encounter with cosmetic product usage."
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS001029

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel